Roenfanz Hanna F, Nicolau David P, Kuti Joseph L
Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA.
Center for Anti-Infective Research & Development, Hartford Hospital, Hartford, CT, USA.
J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Jul 1;1261:124654. doi: 10.1016/j.jchromb.2025.124654. Epub 2025 May 14.
Sulbactam-durlobactam is a combination β-lactam/β-lactamase inhibitor antibiotic approved in the United States for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia due to susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. A liquid chromatography tandem mass spectrometry method for the quantification of sulbactam and durlobactam in human plasma and aqueous matrices has been developed and validated. The standard curves for each drug were linear over the range 0.5 to 50 μg/mL and use the isotopic analogs sulbactam-d and [C, N]-durlobactam as internal standards for their respective analytes. This simple, reproducible method for the determination of sulbactam and durlobactam concentrations was developed with the intent to conduct future pharmacokinetic analyses and to guide clinical laboratories in the development of a therapeutic drug monitoring assay.
舒巴坦-度洛巴坦是一种β-内酰胺/β-内酰胺酶抑制剂联合抗生素，在美国被批准用于治疗因鲍曼不动杆菌-醋酸钙复合菌易感菌株引起的医院获得性和呼吸机相关性细菌性肺炎的成年患者。已开发并验证了一种液相色谱串联质谱法，用于定量人血浆和水性基质中的舒巴坦和度洛巴坦。每种药物的标准曲线在0.5至50μg/mL范围内呈线性，并使用同位素类似物舒巴坦-d和[C,N]-度洛巴坦作为各自分析物的内标。开发这种简单、可重复的测定舒巴坦和度洛巴坦浓度的方法，旨在进行未来的药代动力学分析，并指导临床实验室开展治疗药物监测测定。
